Evonik unveils latest global trial results MetAMINO
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
Aurigene.AI is an end-to-end solution for small molecule drug discovery
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
The average time of dilation lasts three to eight hours
These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.
Application based on results from the TROPION-Breast01 Phase III trial
Establishment of 220 smart classrooms across Uttar Pradesh, Uttarakhand, and Himachal Pradesh
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
Subscribe To Our Newsletter & Stay Updated